The current guidelines state that adjunctive aripiprazole is typically initiated at 2.5—5 mg/day and titrated upward as tolerated to a maximum dose of 30 mg/day. In the study cited for this recommendation (2), adjunctive aripiprazole was initiated at 5 mg/day and, if tolerability permitted, increased to the target dose of 10 mg/day at the start of week 2. The dose could be reduced to 2 mg if necessary for tolerability. The maximal dose in the study was 20 mg/day. There is no recommendation in the product information for a maximum dose of 30 mg/day for aripiprazole adjunctive to antidepressants. When making treatment decisions, it is important to consider the doses that were studied in three large, placebo-controlled, double-blind clinical trials for aripiprazole adjunctive to antidepressants in the treatment of major depressive disorder (2—4), and these data provide the foundation for the recommended doses in the product information.